Maria Gion

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Journal: NPJ breast cancer

Published: December 15, 2025

Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.

Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: May 09, 2025

Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.

Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: May 08, 2025

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.

Journal: Nature medicine

Published: March 12, 2025

Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.

Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.

Journal: EClinicalMedicine

Published: March 06, 2025

Obesity, overweight and breast cancer: new clinical data and implications for practice.

Obesity, overweight and breast cancer: new clinical data and implications for practice.

Journal: Frontiers in oncology

Published: February 19, 2025

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.

Journal: Breast cancer research : BCR

Published: December 17, 2024

Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Journal: Nature medicine

Published: December 09, 2024

Moving toward response-adapted trials in oncology.

Moving toward response-adapted trials in oncology.

Journal: Nature medicine

Published: November 11, 2024

In silico decrypting of the bystander effect in antibody-drug conjugates for breast cancer therapy.

In silico decrypting of the bystander effect in antibody-drug conjugates for breast cancer therapy.

Journal: Scientific reports

Published: November 06, 2024

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.

Journal: Nature medicine

Published: November 05, 2024

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Journal: Frontiers in immunology

Published: October 18, 2024

Showing 1-12 of 49

Last Updated: 09/26/2026